Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.

Agilent Technologies Inc. and Oxford Gene Technology (OGT) announced they have expanded an existing partnership into an exclusive agreement for Agilent to provide OGT with oligonucleotide microarrays ...

STAMFORD, Conn., March 16, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (GeneDx) (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, announced new ...

Researchers at Baylor College of Medicine and Roche NimbleGen Inc. have published details of an efficient and cost-effective method for capturing targeted regions of the genome via NimbleChip™ ...

Modern laboratory techniques for the detection of novel human viruses are greatly needed as physicians and epidemiologists increasingly deal with infectious diseases caused by new or previously ...

Background Monogenic disorders are a major cause of fetal structural anomalies. Most genetic diagnoses involve de novo, biallelic or X linked variants; however, inherited variants in autosomal ...

In the rapidly evolving field of genomics, a new class of non-coding RNAs has captured the attention of researchers worldwide - circular RNAs (circRNAs). Unlike their linear counterparts, circRNAs are ...

The panel ensures compatibility with our previous autosomal Family Finder tests plus all the autosomal transfers we ...

JA Rosenfeld is an employee of Signature Genomic Laboratories, a subsidiary of PerkinElmer, Inc. The authors have no other relevant affiliations or financial involvement with any organization or ...

MiRNA microarray kits and reagents market is experiencing robust growth driven by rising demand for precision diagnostics, biomarker discovery, and translational research. Expansion of oncology ...

(MENAFN- GlobeNewsWire - Nasdaq) Gene-driven therapies dominate therapeutic strategies, propelled by cutting-edge sequencing platforms and unique biomarker insights. Despite inconsistent regulations, ...